Breaking News Instant updates and real-time market news.

CTRV

ContraVir Pharmaceuticals

$0.53

-0.0398 (-6.98%)

, ABBV

AbbVie

$89.70

0.9 (1.01%)

04:55
11/13/18
11/13
04:55
11/13/18
04:55

American Association of Liver Diseases to hold a meeting

Liver Meeting 2018 will be held in San Francisco on November 9-13.

CTRV

ContraVir Pharmaceuticals

$0.53

-0.0398 (-6.98%)

ABBV

AbbVie

$89.70

0.9 (1.01%)

AGN

Allergan

$163.82

-1.77 (-1.07%)

ALXN

Alexion

$118.57

-4.88 (-3.95%)

BAYRY

Bayer

$0.00

(0.00%)

BOLD

Audentes Therapeutics

$23.60

-0.41 (-1.71%)

BMY

Bristol-Myers

$52.86

-0.54 (-1.01%)

BSX

Boston Scientific

$36.92

-1.68 (-4.35%)

CBAY

CymaBay

$10.49

-1.07 (-9.26%)

DOVA

Dova Pharmaceuticals

$16.52

-0.3803 (-2.25%)

DVAX

Dynavax

$12.17

0.09 (0.75%)

EXEL

Exelixis

$15.94

-0.72 (-4.32%)

ESALY

Eisai

$0.00

(0.00%)

GILD

Gilead

$70.49

-0.69 (-0.97%)

ICPT

Intercept

$100.79

-8.12 (-7.46%)

IQV

Iqvia

$121.10

-3.08 (-2.48%)

MRK

Merck

$74.68

-0.19 (-0.25%)

NVS

Novartis

$88.23

-0.98 (-1.10%)

NVO

Novo Nordisk

$44.55

-0.4 (-0.89%)

ONVO

Organovo

$1.12

-0.025 (-2.18%)

OSUR

OraSure

$13.49

0.475 (3.65%)

RCUS

Arcus Biosciences

$11.99

-0.31 (-2.52%)

RTRX

Retrophin

$24.80

-0.98 (-3.80%)

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 27

    Nov

  • 27

    Nov

  • 29

    Nov

  • 01

    Dec

  • 03

    Dec

  • 11

    Jan

  • 14

    Jan

  • 16

    Feb

  • 18

    Feb

  • 20

    May

  • 30

    Jun

CTRV ContraVir Pharmaceuticals
$0.53

-0.0398 (-6.98%)

07/10/18
MAXM
07/10/18
UPGRADE
Target $3
MAXM
Buy
ContraVir Pharmaceuticals upgraded to Buy at Maxim on extended funding runway
As reported earlier, Maxim analyst Jason McCarthy upgraded ContraVir Pharmaceuticals to Buy from Hold with a price target of $3, saying the company's completed $10.8M equity financing gives it an operating cash runway into early 2019. The analyst also cites his positive expectations from the TXL+CRV431 combination regimens in the U.S. and E.U., with phase 1b/2 program readouts expected in Q4 or Q1 of FY19.
02/13/18
02/13/18
DOWNGRADE

Hold
ContraVir Pharmaceuticals downgraded to Hold at Maxim
As previously reported, Maxim analyst Jason Kolbert downgraded ContraVir Pharmaceuticals to Hold from Buy after the company announced that the FDA agrees the 505b pathway is valid for TXL and as he believes the company will need to raise capital soon. The analyst notes that his fundamental positive outlook on TXL has not changed, however balance sheet concerns represent a key risk to the ContraVir story.
07/10/18
MAXM
07/10/18
UPGRADE
MAXM
Buy
ContraVir Pharmaceuticals upgraded to Buy from Hold at Maxim
02/13/18
MAXM
02/13/18
DOWNGRADE
MAXM
Hold
ContraVir Pharmaceuticals downgraded to Hold from Buy at Maxim
ABBV AbbVie
$89.70

0.9 (1.01%)

11/06/18
ARGS
11/06/18
NO CHANGE
Target $115
ARGS
Buy
AbbVie price target lowered to $115 from $130 at Argus
Argus analyst David Toung lowered his price target on AbbVie to $115 to reflect the competitive environment for its Humira sales from biosimilars in Europe, but also kept his Buy rating and raised his FY18 EPS view by 9c to $7.91 and FY19 by 12c to $9.00. The analyst says Humira should continue to post "solid growth" in the U.S. markets, and also cites the prospects of its Imbruvica, Venclexta Orilissa and hepatitis C drugs along with its remaining product pipeline. Toung contends that the "incremental sales of new faster-growing products can more than offset the expected decline in overseas sales of Humira".
10/30/18
NOMU
10/30/18
NO CHANGE
Target $140
NOMU
Buy
Galapagos price target raised to $140 from $124 at Nomura Instinet
Nomura Instinet analyst Christopher Marai raised his price target for Galapagos NV to $140 following last week's Q3 results and the sale of its partnered-cystic fibrosis program back to AbbVie (ABBV) for $45M upfront and $200M in milestones. The analyst views the upfront payments as upside to expectations and keeps a Buy rating on Galapagos shares.
10/25/18
BMOC
10/25/18
NO CHANGE
Target $192
BMOC
Outperform
Vertex price target lowered to $192 from $204 at BMO Capital
BMO Capital analyst Do Kim lowered his price target on Vertex (VRTX) to $192, saying its in-line Q3 results may be overshadowed by the AbbVie (ABBV) decision to license rights to Galapagos (GLPG) cystic fibrosis program, since the expectation was for the collaboration to dissolve. The analyst adds that while the Galapagos interim data did not make competitive inroads on Vertex therapies, he is still lowering the the FY19 EPS view for the latter to $4.43 from $5.13 on slow ex-U.S. growth amid reimbursement challenges and higher operating expenses. Longer term, Kim keeps his Outperform rating on Vertex.
11/02/18
PIPR
11/02/18
NO CHANGE
PIPR
AbbVie Q3 results do not convince Piper Jaffray to get off sidelines
Piper Jaffray analyst Christopher Raymond maintained a Neutral rating on AbbVie after the company's Q3 earnings results, which Raymond noted were better than expected. However, the analyst was cautious given management's indication of growing headwinds, which he believes "portend a meaningful downward revision to FY19 consensus." Additionally, Raymond sees AbbVie "married to the prospects of Humira," which he believes now faces international headwinds competing with four biosimilars.
AGN Allergan
$163.82

-1.77 (-1.07%)

11/12/18
LEER
11/12/18
INITIATION
Target $220
LEER
Outperform
Allergan initiated with an Outperform at Leerink
Leerink Partners analyst Marc Goodman started Allergan with an Outperform rating and $220 price target.
11/01/18
MZHO
11/01/18
NO CHANGE
Target $213
MZHO
Buy
Allergan selloff on 'optimistic' 2019 estimates overdone, says Mizuho
Mizuho analyst Irina Koffler lowered her price target for Allergan shares to $213 from $220 but remains a buyer of the stock with a Buy rating. The analyst attributes the weakness in shares of Allergan to "overly optimistic" 2019 estimates. However, the selloff is overdone, Koffler tells investors in a research note.
10/31/18
FBCO
10/31/18
NO CHANGE
Target $202
FBCO
Outperform
Allergan price target lowered to $202 from $213 at Credit Suisse
Credit Suisse analyst Vamil Divan lowered his price target for Allergan to $202 from $213 following Q3 earnings. The analyst notes that Q3 quarterly performance and 2018 guidance raise was somewhat expected, but comments around the outlook of some important products and operating margins for 2019 highlight new challenges the company must overcome while waiting for the pipeline to deliver. He reiterates an Outperform rating on the shares.
10/31/18
HCWC
10/31/18
NO CHANGE
Target $12.5
HCWC
Sell
H.C. Wainwright backs Sell rating on Ironwood with Linzess seen disappointing
H.C. Wainwright analyst Raghuram Selvaraju reiterated his Sell rating on shares of Ironwood Pharmaceuticals (IRWD) after partner Allergan (AGN) indicated with its quarterly earnings report that it expects future revenue growth for Linzess to be in the low- to mid-single digits. He also believes that Ironwood's own financials for the third quarter may prove even more disappointing due to the company's history of poor operational expense control, Selvaraju added. He keeps a $12.50 price target on Ironwood shares ahead of its quarterly report, due on November 6.
ALXN Alexion
$118.57

-4.88 (-3.95%)

10/10/18
10/10/18
UPGRADE

Strong Buy
RA Pharmaceuticals upgraded to Strong Buy ahead of Phase 2 data at Raymond James
As previously reported, Raymond James upgraded RA Pharmaceuticals (RARX) to Strong Buy from Outperform with a $28 price target. Analyst Steven Seedhouse expects Phase 2 data for lead subcutaneous C5 inhibitor zilucoplan in generalized myasthenia gravis expected around YE18 to demonstrate a treatment benefit in a mixed refractory/non-refractory patient population and be competitive with Alexion's (ALXN) Soliris. Seedhouse believes a positive Phase 2 readout could be worth $1B in market cap at least and could treat a broader population of patients than Soliris given subcutaneous administration and pricing leverage.
10/15/18
PIPR
10/15/18
NO CHANGE
PIPR
Piper lists names to own in Biopharma after recent selloff
Piper Jaffray's biopharma analyst team highlighted names to own in the Biopharma sector following the recent selloff of the broader market. The firm's ideas include: Adamas Pharmaceuticals (ADMS), Agios Pharmaceuticals (AGIO), Agios Pharmaceuticals (ALNY), Alexion (ALXN), Bluebird Bio (BLUE), BioMarin (BMRN), CymaBay (CBAY), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), Jazz Pharmaceuticals (JAZZ), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and Xencor (XNCR).
10/31/18
HCWC
10/31/18
NO CHANGE
Target $24
HCWC
Buy
Dicerna price target raised to $24 after Lilly, Alexion pacts at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target on Dicerna (DRNA) shares to $24 from $20 after the company announced collaborations with Eli Lilly (LLY) and Alexion Pharmaceuticals (ALXN). Arce views these partnerships as further strong validation of Dicerna's GalXC RNAi platform and keeps a Buy rating on the shares.
10/24/18
PIPR
10/24/18
NO CHANGE
Target $177
PIPR
Overweight
Piper 'perplexed' by Alexion earnings selloff, says buy shares
Piper Jaffray analyst Christopher Raymond recommends using the selloff today in shares of Alexion Pharmaceuticals (ALXN) as a buying opportunity. The company reported "yet another strong beat/raise quarter and continued impressive pipeline progress," Raymond tells investors in a research note. The analyst sees "little to quibble with commercially" with Soliris' "continued strength and a rapidly expanding margin profile." Raymond is "perplexed" by the stock pullback and keeps an Overweight rating on Alexion with a $177 price target. The stock could be weak on fears over Roche's (RHHBY) update on RG6107, the analyst adds. He says Alexion remains one of his favorite large caps to own "well into 2019."
BAYRY Bayer
$0.00

(0.00%)

08/27/18
08/27/18
UPGRADE
Target $34

Neutral
Portola Pharmaceuticals upgraded to Neutral as MARINER sinks at Credit Suisse
As previously reported, Credit Suisse analyst Vamil Divan upgraded Portola Pharmaceuticals (PTLA) to Neutral from Underperform after Johnson & Johnson (JNJ)/Bayer (BAYRY) presented disappointing data for Xarelto in the acute medically ill population at ESC. The analyst notes that the data avoids a worst case scenario for Portola's Bevyxxa by essentially removing a potentially strong competitor, but does put the pressure on Portola to successfully change medical practice on its own, without help from a larger player such as Johnson & Johnson. Divan also raised his price target on Portola's shares to $34 from $28.
09/11/18
EXAN
09/11/18
DOWNGRADE
EXAN
Neutral
Bayer downgraded to Neutral from Outperform at Exane BNP Paribas
09/18/18
09/18/18
UPGRADE

Bayer upgraded to Buy from Hold at M.M. Warburg
M.M. Warburg analyst Ulrich Huwald upgraded Bayer to Buy and raised his price target for the shares to EUR 88.50 from EUR 85.
09/20/18
SBSH
09/20/18
UPGRADE
SBSH
Buy
Bayer upgraded to Buy from Neutral at Citi
Citi analyst Peter Verdult upgraded Bayer to Buy saying the current risk/reward is "difficult to ignore" with investor sentiment at "rock bottom." The analyst believes the negative earnings revisions have likely bottomed out.
BOLD Audentes Therapeutics
$23.60

-0.41 (-1.71%)

11/07/18
WBLR
11/07/18
DOWNGRADE
WBLR
Market Perform
Audentes downgraded to Market Perform from Outperform at William Blair
William Blair analyst Raju Prasad downgraded Audentes Therapeutics to Market Perform following the company's Q3 results. The analyst says increased competition in Pompe disease is giving him pause.
10/12/18
HCWC
10/12/18
NO CHANGE
Target $33
HCWC
Buy
Audentes Therapeutics price target lowered to $33 from $40 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Audentes Therapeutics to $33 after the company closed another secondary offering at $29 per share, which he notes represents a 17% discount to the January offering, which diluted shareholders by about 14%. The latest offering "leaves more than a sour taste in our mouths," Chattopadhyay tells investors in a research note. He believes Audentes had "no dire need to access the capital markets" and finds the timing and pricing of the offering "to be a little suspect." However, Chattopadhyay keeps a Buy rating on Audentes Therapeutics.
10/09/18
GUGG
10/09/18
INITIATION
GUGG
Neutral
Audentes Therapeutics initiated with a Neutral at Guggenheim
Guggenheim analyst Whitney Ijem initiated Audentes Therapeutics with a Neutral rating, saying that at current levels they believe the potential revenues are already reflected.
11/07/18
11/07/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Freeport McMoRan (FCX) downgraded to Underperform from Sector Perform at RBC Capital with analyst Stephen Walker saying he points to the company's premium valuation ahead of what he expects to be a decline in 2019 production. 2. Zillow (Z, ZG) downgraded to Sell from Hold at Zelman and to Negative from Neutral at Susquehanna. 3. Mindbody (MB) downgraded to Neutral from Buy at UBS and Roth Capital as well as to Neutral from Overweight at JPMorgan. 4. Frontier Communications (FTR) downgraded to Sell from Neutral at UBS with analyst Batya Levi saying Frontier's free cash flow remains under pressure. 5. Audentes downgraded to Market Perform from Outperform at William Blair with analyst Raju Prasad saying increased competition in Pompe disease is giving him pause. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BMY Bristol-Myers
$52.86

-0.54 (-1.01%)

11/05/18
HCWC
11/05/18
NO CHANGE
Target $47
HCWC
Neutral
Nektar price target lowered to $47 from $54 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Nektar Therapeuticsless than (NKTR) to $47 and keeps a Neutral rating on the shares. While the Phase 3 trial of Opdivo plus NKTR-214 is welcome news, the company faces a crowded frontline renal cell carcinoma treatment landscape and stiff commercial hurdles, Chattopadhyay tells investors in a research note. He believes that unless the NKTR-214 plus Opdivo combination is meaningfully superior to the Opdivo and Yervoy combination, Bristol-Myers (BMY) "may not be willing to muscle the commercial launch, given the cannibalization of its existing franchise."
11/08/18
JEFF
11/08/18
NO CHANGE
Target $73
JEFF
Buy
Nektar price target lowered to $73 from $103 at Jefferies
Jefferies analyst David Steinberg lowered his price target for Nektar Therapeutics (NKTR) to $73 after reducing his assumptions for NKTR-214 to reflect a potentially prolonged delay in non-small-cell lung carcinoma. The analyst, however, keeps a Buy rating on the shares following the company's Q3 results. He points out that Nektar's partnership with Bristol-Myers (BMY) as well as its other collaborations are ramping up.
10/23/18
WOLF
10/23/18
INITIATION
Target $66
WOLF
Outperform
Bristol-Myers reinitiated with an Outperform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated Bristol-Myers with an Outperform and $66 price target.
10/25/18
WELS
10/25/18
NO CHANGE
WELS
Wells Fargo says Trump speech today won't be end of drug pricing proposals
Wells Fargo analyst David Maris notes that Politico and other media outlets are reporting that President Donald Trump will propose several new initiatives to address high drug prices when he speaks later today at the U.S. Department of Health and Human Services. Maris thinks Trump's focus will be on how other countries are "freeloading" on U.S. innovation with lower negotiated pricing, stating that news reports make it appear that the administration is targeting the industry for action, rather than other countries to raise their spending. While Maris acknowledges the timing of the speech being near the mid-term elections, he believes these proposals are simply the follow-though of earlier promises. He also expects this is not the end of proposals to address the issue of U.S. drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
BSX Boston Scientific
$36.92

-1.68 (-4.35%)

10/25/18
ADAM
10/25/18
NO CHANGE
Target $42
ADAM
Buy
Boston Scientific entering 2019 with best fundamentals ever, says Canaccord
Canaccord analyst Jason Mills noted Boston Scientific reported solid Q3 results and said there was nothing in the report to imply a loss of momentum. The analyst believes the company will enter 2019 with its best fundamentals in its history and is very well positioned to deliver organic revenue growth above its peers. Mills reiterated his Buy rating and raised his price target to $42 from $40 on Boston Scientific shares.
10/25/18
PIPR
10/25/18
NO CHANGE
Target $25
PIPR
Overweight
Nuvectra recent selloff brings 'excellent entry point,' says Piper Jaffray
Piper Jaffray analyst Matt O'Brien believes the recent Q3 results of neuromodulation incumbents, Boston Scientific (BSX) and Abbott (ABT), "reinforce the dynamic characteristics" of the spinal cord stimulation marketplace. Nuvectra's (NVTR) Algovita is likely one of the beneficiaries and could post upside in the quarter, O'Brien tells investors in a research note. The analyst says Nuvectra continues to be his top-microcap pick with a "reasonable valuation." Further, the recent softness in the shares "provides an excellent entry point for a name that is still in the early innings of gaining SCS share." He keeps an Overweight rating on Nuvectra with a $25 price target.
10/24/18
PIPR
10/24/18
NO CHANGE
Target $40
PIPR
Overweight
Piper continues to recommend purchase of Boston Scientific after earnings
Piper Jaffray analyst Matt O'Brien says that while currency proved more of a drag than expected in Boston Scientific's Q3, the company's outlook remains "strong." There were a couple areas of modest weakness in the quarter, but the key growth drivers, namely Neuromod, MedSurg and Structural Heart, were "quite strong again," O'Brien tells investors in a post-earnings research note. The analyst believes Boston Scientific's market opportunities, along with new products, "will continue to buoy revenue results" in 2019 and 2020. He encourages investors to start or build positions in the name and keeps an Overweight rating on Boston Scientific with a $40 price target.
10/22/18
COWN
10/22/18
NO CHANGE
Target $42
COWN
Outperform
Boston Scientific price target raised to $42 from $39 at Cowen
Cowen analyst Joshua Jennings raised his price target on Boston Scientific to $42 from $39. He believes the story remains compelling given the company's sustainable, above-peer growth combined with regular operating margin expansion and double digit earnings growth. Jennings reiterated his Outperform rating on Boston Scientific shares.
CBAY CymaBay
$10.49

-1.07 (-9.26%)

08/09/18
PIPR
08/09/18
NO CHANGE
Target $30
PIPR
Overweight
CymaBay price target raised to $30 from $16 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren raised his price target on CymaBay to $30 and kept his Overweight rating, saying he expects the company's cinical progress and additional updates in PBC and NASH to drive its share price higher over the next 12-18 months. The analyst expects the PBC phase 2 data on seladelpar expected in Q4 to be "confirmartory", de-risking the subsequent phase 3 trial. He adds that the phase 2b proof of concept NASH study will hopefully show "clinically meaningful effects based on the preclinical data and differentiated mechanism of action".
06/28/18
RAJA
06/28/18
INITIATION
Target $20
RAJA
Outperform
CymaBay initiated with an Outperform at Raymond James
Raymond James analyst Steven Seedhouse initiated CymaBay with an Outperform and $20 price target.
06/06/18
HCWC
06/06/18
NO CHANGE
Target $23
HCWC
Buy
CymaBay price target raised to $23 from $21 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for CymaBay Therapeutics to $23 saying the company is well positioned to successfully execute its strategy with seladelpar. The analyst reiterates a Buy rating on the shares.
DOVA Dova Pharmaceuticals
$16.52

-0.3803 (-2.25%)

08/29/18
RAJA
08/29/18
INITIATION
Target $44
RAJA
Outperform
Dova Pharmaceuticals initiated with an Outperform at Raymond James
Raymond James analyst Laura Chico initiated Dova Pharmaceuticals with an Outperform and $44 price target. Chico's physician survey indicates suggest a need for novel treatments like Dova's Droptelet and said investor expectations are modest, providing a favorable setup for shares.
09/17/18
JEFF
09/17/18
NO CHANGE
Target $40
JEFF
Buy
Physician poll positive for Dova Pharmaceuticals' Doptelet, says Jefferies
Jefferies analyst Eun Yang says her physician poll results on Dova Pharmaceuticals' Doptelet are "highly encouraging." The analyst sees high awareness and more favorable rates upon use of Doptelet versus current standard of care, or platelet transfusion, three months into launch as positives. Further, Doptelet preference among the polled doctors surpasses competitor Mulpleta despite a higher list pricing, Yang tells investors in a research note. She keeps a Buy rating on Dova with a $40 price target.
04/26/18
LTCO
04/26/18
INITIATION
Target $65
LTCO
Buy
Dova Pharmaceuticals initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Matthew Kaplan started Dova Pharmaceuticals with a Buy rating and $65 price target.
07/09/18
LEER
07/09/18
DOWNGRADE
LEER
Market Perform
Dova Pharmaceuticals downgraded to Market Perform from Outperform at Leerink
DVAX Dynavax
$12.17

0.09 (0.75%)

08/07/18
CANT
08/07/18
NO CHANGE
Target $30
CANT
Overweight
Dynavax price target raised to $30 from $27 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Dynavax Technologies to $30 and reiterates an Overweight rating on the shares following the company's Q2 results. The analyst believes there are a "number of opportunities in the near future for Dynavax that could lead to upside for the company," including future Heplisav-B vaccine sales and a Phase 3 trial initiation for SD-101 in advanced melanoma.
10/22/18
RBCM
10/22/18
NO CHANGE
Target $26
RBCM
Outperform
Dynavax price target raised to $26 from $23 at RBC Capital
RBC Capital analyst Brian Abrahams raised his price target on Dynavax to $26 and kept his Outperform rating after its PD-1 melanoma presentations at the European Society for Medcal Oncology Congress this weekend. The analyst notes that the findings revealed no new safety signals and continued abscopal responses across both PD-L1 positive and negative patients, which he views as the "best-case scenario for this data cut".
10/22/18
CANT
10/22/18
NO CHANGE
Target $32
CANT
Overweight
Dynavax price target raised to $32 from $30 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Dynavax Technologies (DVAX) to $32 following presentations at the European Society for Medical Oncology Congress. The data present the case for why Merck (MRK) could be a potential partner, Piros tells investors in a research note. He keeps an Overweight rating on Dynavax.
10/22/18
JPMS
10/22/18
NO CHANGE
Target $27
JPMS
Overweight
JPMorgan expects 35%-50% rally in Dynavax after 'clear win' data
JPMorgan analyst Anupam Rama views Dynavax Technologies' update to the SD-101 plus pembrolizumab combination program as a "clear win." The analyst's focus is on the treatment naive melanoma data set, given that the presentation has the most patients at the go-forward 2mg dose level. These data hit the analyst's "upside / homerun scenario" with a 70% overall response rate. Rama sees Dynavax shares trading up in the 35%-50% range following this weekend's update. He keeps an Overweight rating on the name with a $27 price target. The stock in premarket trading is up 21%, or $2.26, to $13.15.
EXEL Exelixis
$15.94

-0.72 (-4.32%)

11/02/18
NEED
11/02/18
NO CHANGE
Target $30
NEED
Buy
Exelixis well positioned for future I/O combos, says Needham
Needham analyst Chad Messer said cabozantinib is "becoming the drug of choice in second line treatment in RCC" and he believes immuno-oncology combos will support future growth. Exelixis is running several clinical programs investigating cabozantinib in combination with I/O drugs, noted Messer, who keeps a Buy rating and $30 price target on Exelixis following the company's Q3 report.
09/21/18
PIPR
09/21/18
NO CHANGE
Target $29
PIPR
Overweight
Piper Jaffray reiterates Overweight rating on Exelixis after CHMP decision
After Ipsen (IPSEY) announced a positive CHMP decision for Cabometyx as a monotherapy for the treatment of hepatocellular carcinoma, Piper Jaffray analyst Edward Tenthoff noted that Exelixis (EXEL) is eligible for tiered royalties of 22-26% after $100M in sales of the drug in Europe. He expects final EMA approval in coming months and also expects the FDA to approve Cabometyx in liver cancer by the January 14 PDUFA date, Tenthoff tells investors. He reiterated an Overweight rating and $29 price target on Exelixis shares.
11/04/18
PIPR
11/04/18
NO CHANGE
Target $26
PIPR
Overweight
Exelixis price target lowered to $26 from $29 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for Exelixis to $26 from $29, while reiterating an Overweight rating on the shares. The analyst notes the company delivered another beat with U.S. CABOMETYX sales of $158M in Q3. Although I-O is beginning to dominate front-line RCC, Tenthoff believes CABO is competitively positioned in certain patients and with ongoing I-O combo studies of its own. Next, he expects CABOMETYX label expansion in hepatocellular carcinoma with approval by the January 14th PDUFA date. The analyst now forecasts CABOMETYX sales of $595M in 2018, $826M in 2019, peaking at $1.38B in 2024.
10/08/18
PIPR
10/08/18
NO CHANGE
PIPR
Piper Jaffray optimistic on Exelixis' Cabometyx
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $29 price target on Exelixis. The analyst noted that Exelixis initiated a Phase III trial of Cabometyx in radioiodine-refractory differentiated thyroid cancer, or DTC. He is looking for continued Cabometyx adoption in first and second-line renal cell carcinoma with sales of $572M this year, and sees Cabometyx approval in 2nd-line liver cancer by the January 14 PDUFA date, which will help drive sales to $873M in 2019.
ESALY Eisai
$0.00

(0.00%)

08/28/18
PIPR
08/28/18
NO CHANGE
PIPR
Overweight
Piper says Biogen PRIME data has little to change minds of bulls or bears
After Biogen (BIIB) and Eisai (ESALY) announced another year's worth of long term extension data from their ongoing PRIME Phase 1b study of aducanumab, Piper Jaffray analyst Christopher Raymond said he sees little in the release to change the minds of either A-beta bulls or A-beta bears. Raymond, who continues to look toward a full Phase 3 data read-out in early 2020 as the key event for aducanumab, keeps an Overweight rating on Biogen shares.
07/06/18
MSCO
07/06/18
NO CHANGE
Target $369
MSCO
Overweight
Biogen likely to be up 5%-10% on positive Alzheimer's data, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison said the fact that Eisai (ESALY) and Biogen's (BIIB) BAN2401 trial achieved positive topline results at an 18 month landmark analysis is a "clear positive" for the perception of aducanumab and he expects Biogen's shares to be up 5% to over 10% following the news. Harrison added that he would expect full data to be reported at the CTAD meeting in October as he thinks the AAIC meeting coming up in late July is too close. He keeps an Overweight rating and $369 price target on Biogen shares.
07/10/18
MZHO
07/10/18
NO CHANGE
MZHO
Buy
Biogen, Eisai not sharing details on BAN2401 presentation at AAIC, says Mizuho
After Biogen (BIIB) and partner Eisai's (ESALY) recent announcement that BAN2401 demonstrated statistically significant slowing in clinical decline and reduction of amyloid beta accumulation in a trial of Alzheimer's patients, Mizuho analyst Salim Syed said he has checked with both companies and neither is divulging any details about what sort of data on the trial will be shared at the upcoming AAIC meeting. He maintains a Buy rating and $423 price target on Biogen shares.
07/06/18
NOMU
07/06/18
UPGRADE
NOMU
Buy
Eisai upgraded to Buy from Neutral at Nomura Instinet
GILD Gilead
$70.49

-0.69 (-0.97%)

10/26/18
JEFF
10/26/18
NO CHANGE
Target $95
JEFF
Buy
Gilead shares can rebound to $80 over next 6-9 months, says Jefferies
Jefferies analyst Michael Yee continues to think Gilead Sciences is being "underappreciated" following last night's "solid' Q3 results. Gilead is positioned well into 2019, Yee tells investors in a post-earnings research note. He sees several Phase III catalysts over the next 6-9 months that can help Gilead rebound back to $80 per share and closer to his unchanged price target of $95.
10/26/18
CANT
10/26/18
NO CHANGE
Target $88
CANT
Overweight
Cantor likes the setup for Gilead over the next six months
Cantor Fitzgerald analyst Alethia Young raised her price target for Gilead Sciences to $88 from $87 and reiterates an Overweight rating on the shares following last night's Q3 results. Gilead beat top and bottom line consensus expectations as the Biktarvy launch remains strong in HIV, Young tells investors in a post-earnings research note. She likes the setup for shares over the next six months, but acknowledges that investors may be waiting for new management to be in place. The analyst remains positive as she thinks pipeline expectations remain low.
10/31/18
MZHO
10/31/18
NO CHANGE
Target $94
MZHO
Buy
Mizuho says concerns over UnitedHealth program impact on Gilead seem unwarranted
Mizuho analyst Salim Syed blames UnitedHealth's (UNH) introduction of a new a program, called "My ScriptRewards," that will try to convince plan participants to take a cheaper HIV regimen in return for $500 in debit cards for the weakness in shares of Gilead (GILD). However, the analyst views the worries as unwarranted, noting that Cimduo is the "common thread" between all of the regimens that UnitedHealth's program calls out and it is an inferior drug to Gilead's Biktarvy. Biktarvy is the backbone of the number one recommended regimen according to HHS treatment guidelines, noted Syed, who keeps a Buy rating and $94 price target on Gilead shares.
10/31/18
EVER
10/31/18
NO CHANGE
EVER
Outperform
Gilead sales not at risk from UnitedHealth promotions, says Evercore ISI
Evercore ISI analyst Umer Raffat attributes the pullback today in shares of Gilead Sciences (GILD) to concerns over the company's HIV franchise given UnitedHealth's (UNH) promotions of cheaper alternatives. UnitedHealth (UNH) is offering a rewards plan to patients starting with HIV medications to help promote the use of lower priced drugs, Jefferies analyst Michael Yee pointed out earlier today in a research note. Raffat, however, does not see risk to Gilead's sales from the promotions. UnitedHealth's is proposing a switch to two separate tablets, which is not in the HIV guidelines today, says the analyst. He keeps an Outperform rating on Gilead shares, which are down 6% to $68.00 in afternoon trading.
ICPT Intercept
$100.79

-8.12 (-7.46%)

11/01/18
CANT
11/01/18
NO CHANGE
Target $170
CANT
Overweight
Cantor 'very positive' on Intercept shares following recent pullback
Cantor Fitzgerald analyst Alethia Young is "very positive" on shares of Intercept Pharmaceuticals following the recent selloff and views the stock as a top pick over 2019. Ocaliva sales in Q3 were roughly in line with consensus estimates, Young tells investors in a post-earnings research note. She thinks the risk/reward is attractive, with potential upside 130% versus downside risk of 50%, into the Phase 3 NASH readout. The analyst reiterates an Overweight rating on Intercept with a $170 price target.
10/02/18
JEFF
10/02/18
NO CHANGE
Target $135
JEFF
Buy
Jefferies sees Intercept moving higher after 'mixed' Gilead data
Jefferies analyst Michael Yee views Gilead Sciences' (GILD) new six-month nonalcoholic steatohepatitis data as "mixed and undifferentiated." As such, he thinks shares of Intercept Pharmaceuticals (ICPT) probably continue to move higher. The stock is likely to retrace back up into year-end and the first half of 2019 as Street realizes Intercept's Phase III will be positive and de-risked, Yee tells investors in a research note. He says the company has had various competitor Farnesoid X receptor data in Phase I/II read out over the past year or and that these have ended up not too differentiated. This has removed some of the competitive overhang on Intercept, the analyst contends. Yee keeps a Buy rating on the shares with a $135 price target.
11/05/18
STFL
11/05/18
NO CHANGE
Target $35
STFL
Buy
Stifel bullish on Galmed ahead of Phase 3 NASH trial
Stifel analyst Adam Walsh noted that Galmed (GLMD) announced along with its Q3 earnings report that the Phase 3 ARMOR study of lead product candidate Aramchol will initiate at the end of Q2 or early in Q3 of 2019. Design details aren't finalized, but management guided towards a design similar to Intercept's (ICPT) ongoing pivotal study of OCA in NASH, said Walsh. He remains bullish on Galmed shares heading into the ARMOR study, highlighting that the company's Phase 2b trial showed strong trends on the two NASH regulatory approvable endpoints along with clinically meaningful NASH resolution. Walsh keeps a Buy rating and $35 price target on Galmed shares.
10/02/18
10/02/18
DOWNGRADE

Outperform
Intercept downgraded to Outperform on valuation at Raymond James
As previously reported, Raymond James downgraded Intercept to Outperform from Strong Buy and raised its price target to $141 from $126. Analyst Steven Seedhouse said risk/reward is favorable ahead of the pivotal REGENERATE data in 1H 2019, but said some of the binary upside from his original thesis is reflected in shares.
IQV Iqvia
$121.10

-3.08 (-2.48%)

10/23/18
RBCM
10/23/18
NO CHANGE
Target $137
RBCM
Outperform
Iqvia price target raised to $137 from $129 at RBC Capital
RBC Capital analyst George Hill raised his price target on Iqvia to $137 and kept his Outperform rating after its Q3 earnings came in at the high end of guidance with higher outlook for earnings expected in FY18. The analyst adds that the most encouraging development was the management's maintained view of the company's next-gen clinical trials solution selling well as well as its expected R&D revenue growth closing the "gap with bookings" by the end of 2019.
10/23/18
LEHM
10/23/18
NO CHANGE
Target $140
LEHM
Overweight
Iqvia price target raised to $140 from $130 at Barclays
Barclays analyst Jack Meehan raised his price target for Iqvia to $140 and reiterates an Overweight rating on the shares following yesterday's "solid" quarter. Despite the "muted" stock reaction for following earnings, there were "several encouraging leading indicators" with the Q3 results that bode well for growth heading into 2019, Meehan tells investors in a research note.
10/22/18
PIPR
10/22/18
NO CHANGE
Target $131
PIPR
Neutral
Iqvia price target raised to $131 from $97 at Piper Jaffray
Piper Jaffray analyst Sean Wieland raised his price target on Iqvia (IQV) to $131 after its Q3 earnings beat, saying that in spite of the FX and ASC606 accounting-related headwinds, the company also posted in-line revenues. The analyst cited cost containment supporting margin upside along with a "raise on profitability metrics". Wieland is also positive on Iqvia expanding its partnership with Salesforce (CRM) which is "designed to provide technology to make clinical trials more efficient". The analyst keeps his Neutral rating, adding that his new price target is also based on the methodology transitioning to a PE multiple from Enterprise Value / EBITDA one to reflect the company's buyback program.
10/09/18
UBSW
10/09/18
NO CHANGE
UBSW
UBS initiates coverage of Life Sciences and Diagnostics Tools sector
UBS analyst Daniel Brennan initiated coverage of the Life Sciences and Diagnostics Tools sector. He said demand is accelerating across his universe but valuations are extended. He expects strong fundamentals to continue into 2019 but he said selectivity is the key. In the group, his Buy ratings include Exact Sciences (EXAS), Iqvia (IQV), NanoString (NSTG), Syneos Health (SYNH) and Thermo Fisher (TMO).
MRK Merck
$74.68

-0.19 (-0.25%)

10/31/18
SBSH
10/31/18
NO CHANGE
Target $84
SBSH
Buy
Merck price target raised to $84 from $79 at Citi
Citi analyst Andrew Baum raised his price target for Merck to $84 and reiterates a Buy rating on the shares. The analyst says his 20%-plus above consensus non-GAAP earnings estimates beyond 2022 are driven by a continued view that the market underestimates Merck's market share in the PDx and PARP spaces with Keytruda and Lynparza respectively.
10/23/18
WOLF
10/23/18
INITIATION
Target $90
WOLF
Outperform
Merck reinitiated with an Outperform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated Merck with an Outperform and $66 price target.
11/06/18
PIPR
11/06/18
NO CHANGE
Target $3
PIPR
Overweight
OncoSec price target lowered to $3 from $5 at Piper Jaffray
After OncoSec (ONCS) reported preliminary Phase 2b KEYNOTE-695 data for Tavo combined with Merck's (MRK) Keytruda in PD-1 refractory melanoma patients, Piper Jaffray analyst Edward Tenthoff said the data, while early, show evidence of clinical activity, adding that he believes duration of response data will be important. However, OncoSec shares are down 52% today, which Tenthoff attributes to the lower response rate compared to prior data in different patients. The analyst keeps an Overweight rating on OncoSec shares, but lowered his price target on the stock to $3 from $5 as he pushed out his approval projections for Tavo by one year in the U.S. and Europe.
NVS Novartis
$88.23

-0.98 (-1.10%)

10/23/18
WOLF
10/23/18
INITIATION
WOLF
Outperform
Novartis reinitiated with an Outperform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated Novartis with an Outperform.
10/29/18
PIPR
10/29/18
NO CHANGE
Target $73
PIPR
Overweight
Glaukos remains 'compelling' name that should be owned, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien says feedback on Glaukos' (GKOS) iStent and Inject was again positive at this weekend's American Academy of Ophthalmology meeting. The products are "proving very safe and efficacious," O'Brien tells investors in a research note. Further, the analyst says he has not heard much, if any, commentary on a procedural slowdown of other microinvasive glaucoma surgery cases following the withdrawal of Novartis' (NVS) CyPass, which he believes should be a positive for Glaukos. O'Brien continues to view Glaukos as a "compelling med tech name that should be owned here." He keeps an Overweight rating on the shares with a $73 price target.
10/29/18
MSCO
10/29/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley sees little impact to Regeneron from competitor data at AAO
Morgan Stanley analyst Matthew Harrison noted that data was presented at the American Academy of Ophthalmology's annual meeting for three potential competitors to Regeneron's (REGN) Eylea - Allergan's (AGN) abicipar pegol, Novartis' (NVS) brolucizumab and Roche's (RHHBY) faricimab. Following the presentations, his view on abicipar and brolucizumab is unchanged and he awaits further late-stage data from faricimab, said Harrison, who sees little impact to Regeneron based on the new data. He maintains an Equal Weight rating on Regeneron shares.
NVO Novo Nordisk
$44.55

-0.4 (-0.89%)

11/01/18
STFL
11/01/18
NO CHANGE
Target $15
STFL
Buy
Stifel says Strongbridge makes 'right move' to improve Recorlev clinical package
Stifel analyst Annabel Samimy acknowledged that Recorlev development timelines are pushed out by Strongbridge Biopharma (SBBP) expanding LOGICS to strengthen the clinical package. While this results in a three-quarter delay, with top-line now expected in the fourth quarter of 2019 and the launch expectation pushed out to 2021, he believes the company is ultimately making "the right move." He added that the sale of North American rights of Macrelin to Novo Nordisk (NVO) represents a 7.5x return in less than 2 years, but that was overshadowed by Q3 results that showed Keveyis adoption is "proving more challenging." Samimy keeps a Buy rating and $15 price target on Strongbridge Biopharma shares.
10/08/18
10/08/18
DOWNGRADE

Neutral
Novo Nordisk downgraded to Neutral on Eli Lilly competition at BofA/Merrill
As previously reported, BofA Merrill Lynch analyst Sachin Jain downgraded Novo Nordisk (NVO) to Neutral from Buy after he lowered his Ozempic forecasts beyond FY23 to account for possible competitive pressure from Eli Lilly's (LLY) GIP/GLP-1. While he does not see competitive pressure on Novo's Ozempic until FY23, he still sees that threat as a sufficient overhang given that the injectable GLP-1 franchise accounts for about 40% of his Novo growth forecast from FY19-23E and about 30% for FY23, Sachin tells investors. He lowered his price target on Novo shares to DKK305 from DKK380.
10/08/18
GUGG
10/08/18
INITIATION
GUGG
Buy
Novo Nordisk initiated with a Buy at Guggenheim
Guggenheim analyst Seamus Fernandez started Novo Nordisk with a Buy rating and DKK 361 price target, stating that he expects quality growth through 2020 and beyond " as long as GLP-1 category price discipline remains."
10/08/18
BOFA
10/08/18
DOWNGRADE
BOFA
Neutral
Novo Nordisk downgraded to Neutral from Buy at BofA/Merrill
ONVO Organovo
$1.12

-0.025 (-2.18%)

OSUR OraSure
$13.49

0.475 (3.65%)

10/23/18
RAJA
10/23/18
INITIATION
RAJA
Market Perform
OraSure resumed with a Market Perform at Raymond James
Raymond James analyst John Hsu resumed coverage on OraSure with a Market Perform saying there is limited visibility on HCV and would like to gain greater comfort with the strategic plan from the new management team before getting more positive on the shares.
11/08/18
ADAM
11/08/18
NO CHANGE
Target $18
ADAM
Buy
OraSure weakness a buying opportunity, says Canaccord
Canaccord analyst Mark Massaro said he would be a buyer of the weakness in OraSure following its Q3 results. He said the report was solid but the guidance may be disappointing to investors while he views it as being conservative. Massaro reiterated his Buy rating and lowered his price target to $18 from $20 on OraSure shares.
07/17/18
ADAM
07/17/18
NO CHANGE
Target $20
ADAM
Buy
OraSure weakness a buying opportunity, says Canaccord
Canaccord analyst Mark Massaro said the weakness in OraSure following a competitor firm's downgrade is a buying opportunity. Massaro disagrees with the downgrade, as he believes the company's strategic review will serve as a catalyst and the Q2 results look achievable. He believes the selloff has provided a compelling opportunity to buy the shares. Massaro reiterated his Buy rating and $20 price target on OraSure, which fell about 6% yesterday to close at $16.28 per share.
07/16/18
07/16/18
DOWNGRADE
Target $19

Equal Weight
OraSure downgraded to Equal Weight with unchanged $19 target at Stephens
As previously reported, Stephens analyst Drew Jones downgraded OraSure to Equal Weight from Overweight, as he feels the "valuable" molecular collection business and long-term prospects for microbiome are largely reflected in the stock at its current levels. While he finds the company's ongoing strategic review "intriguing," Jones does not believe it can be presented in a way to serve as a meaningful near-term catalyst for the stock, he added. Jones maintains a $19 price target on OraSure shares.
RCUS Arcus Biosciences
$11.99

-0.31 (-2.52%)

04/09/18
LEER
04/09/18
INITIATION
Target $21
LEER
Outperform
Arcus Biosciences initiated with an Outperform at Leerink
Leerink initiated Arcus Biosciences with an Outperform and $21 price target.
10/09/18
WEDB
10/09/18
INITIATION
Target $22
WEDB
Outperform
Arcus Biosciences initiated with an Outperform at Wedbush
Wedbush analyst Robert Driscoll started Arcus Biosciences with an Outperform rating and $22 price target. The analyst expects the company's focus on extensive biomarker analyses will allow for future clinical strategies with a high likelihood of success. Further, Driscoll believes the breadth and value of its pipeline is undervalued, and sees an attractive entry point ahead of initial efficacy data next year.
04/09/18
SBSH
04/09/18
INITIATION
Target $25
SBSH
Buy
Arcus Biosciences initiated with a Buy at Citi
Citi analyst Robyn Karnauskas started Arcus Biosciences with a Buy rating and $25 price target. The analyst says that while lead compound data is not expected until the first half of 2019, Arcus' proven management and drugs targeting validated pathway make the company competitive despite the crowded landscape in solid tumors.
04/09/18
04/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Spirit Airlines (SAVE) initiated with a Neutral at UBS. 2. Northern Oil and Gas (NOG) initiated with a Buy at Stifel. 3. Camtek (CAMT) initiated with an Outperform at Northland. 4. Ares Management (ARES) initiated with a Buy at UBS. 5. Arcus Biosciences (RCUS) initiated with an Outperform at Leerink, a Buy at Citi, and a Neutral at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
RTRX Retrophin
$24.80

-0.98 (-3.80%)

08/17/18
ADAM
08/17/18
INITIATION
Target $36
ADAM
Buy
Retrophin initiated with a Buy at Canaccord
Canaccord analyst Michelle Gilson initiated Retrophin with a Buy rating citing what she views as an attractive valuation given the upside potential provided by the clinical stage pipeline. She sees limited downside risk but upside catalysts with POC data for CNSA-001 in early 2019 and Phase 3 FORT data in PKAN in the second half 2019. Gilson has a $36 price target on Retrophin shares.
10/30/18
JEFF
10/30/18
INITIATION
Target $44
JEFF
Buy
Retrophin initiated with a Buy at Jefferies
Jefferies analyst Maury Raycroft started Retrophin with a Buy rating and $44 price target. The company has three Phase III programs and a "robust" commercial portfolio, Raycroft tells investors in a research note. Further, he believes the management team has demonstrated to be reliable with examples of execution.
04/19/18
HCWC
04/19/18
NO CHANGE
Target $182
HCWC
Buy
H.C. Wainwright reiterates Buy on Ligand after Novartis reports Q1
H.C. Wainwright analyst Joseph Pantginis says the Promacta franchise remains strong after Ligand Pharmaceuticals (LGND) partner Novartis (NVS) reported Q1 sales Promacta revenue of $257M. The analyst projects 2018 is the year that Promacta officially reaches blockbuster status, or $1B in sales. Further, he points out that Retrophin (RTRX), another Ligand partner, earlier this month announced that the first patient has been enrolled into the Phase 3 Duplex study using sparsentan to treat patients with focal segmental glomerulosclerosis. Pantginis is encouraged by the start of the Phase 3 saying it has the potential to lock in a fixed 9% royalty to Ligand, if approved. He currently project peak sales of $825M but feels the drug could reach blockbuster status based on its first-to-market status. Pantginis keeps a Buy rating on Ligand Pharmaceuticals with a $182 price target.

TODAY'S FREE FLY STORIES

PDVW

pdvWireless

$39.84

0.06 (0.15%)

16:30
11/17/18
11/17
16:30
11/17/18
16:30
Conference/Events
pdvWireless management to meet with Morgan Stanley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBS

CBS

$57.49

0.23 (0.40%)

16:28
11/17/18
11/17
16:28
11/17/18
16:28
Conference/Events
CBS management to meet with Morgan Stanley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

THS

TreeHouse

$51.92

0.72 (1.41%)

, CAG

Conagra Brands

$33.09

0.66 (2.04%)

12:54
11/17/18
11/17
12:54
11/17/18
12:54
Periodicals
Treehouse Foods stock may have room to gain, Barron's says »

Treehouse Foods (THS)…

THS

TreeHouse

$51.92

0.72 (1.41%)

CAG

Conagra Brands

$33.09

0.66 (2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$194.23

1.83 (0.95%)

12:51
11/17/18
11/17
12:51
11/17/18
12:51
Periodicals
Amgen may be 'a remedy' for tougher times, Barron's says »

Amgen may be a stock that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 01

    Dec

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

AAPL

Apple

$193.42

2 (1.04%)

, LITE

Lumentum

$41.50

0.46 (1.12%)

12:47
11/17/18
11/17
12:47
11/17/18
12:47
Periodicals
Apple stock could continue to slide, Barron's says »

Apple's (AAPL) stock…

AAPL

Apple

$193.42

2 (1.04%)

LITE

Lumentum

$41.50

0.46 (1.12%)

QRVO

Qorvo

$66.32

1.18 (1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$56.39

0.9 (1.62%)

, RDS.B

Royal Dutch Shell

$63.97

0.19 (0.30%)

12:41
11/17/18
11/17
12:41
11/17/18
12:41
Periodicals
Investors may find bargains among oil, natural gas stocks, Barron's says »

Investors have been…

APC

Anadarko

$56.39

0.9 (1.62%)

RDS.B

Royal Dutch Shell

$63.97

0.19 (0.30%)

RDS.A

Royal Dutch Shell

$62.02

0.34 (0.55%)

XOM

Exxon Mobil

$78.99

0.81 (1.04%)

CVX

Chevron

$119.14

2.18 (1.86%)

BP

BP

$40.85

-0.3 (-0.73%)

EOG

EOG Resources

$105.21

3.57 (3.51%)

OXY

Occidental Petroleum

$73.32

0.71 (0.98%)

COG

Cabot Oil & Gas

$25.73

0.09 (0.35%)

EQT

EQT Corporation

$16.62

-0.55 (-3.20%)

HAL

Halliburton

$32.46

0.02 (0.06%)

SLB

Schlumberger

$48.24

0.17 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 18

    Jan

  • 22

    Jan

LB

L Brands

$35.28

-0.41 (-1.15%)

, JCP

J.C. Penney

$1.29

-0.08 (-5.84%)

12:34
11/17/18
11/17
12:34
11/17/18
12:34
Periodicals
Kohl's, Target set to thrive this holiday season, Barron's says »

Store chains have been…

LB

L Brands

$35.28

-0.41 (-1.15%)

JCP

J.C. Penney

$1.29

-0.08 (-5.84%)

TJX

TJX

$51.47

-0.98 (-1.87%)

BBY

Best Buy

$66.41

-1.34 (-1.98%)

TIF

Tiffany

$106.48

0.52 (0.49%)

HD

Home Depot

$177.11

-0.25 (-0.14%)

TGT

Target

$79.67

-1.09 (-1.35%)

KSS

Kohl's

$72.48

-0.7 (-0.96%)

AMZN

Amazon.com

$1,593.59

-26.41 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 28

    Nov

  • 04

    Dec

  • 05

    Dec

  • 03

    Mar

T

AT&T

$30.30

0.18 (0.60%)

, FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

09:18
11/17/18
11/17
09:18
11/17/18
09:18
OnTheFly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

T

AT&T

$30.30

0.18 (0.60%)

FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

FOXA

21st Century Fox

$48.18

-0.11 (-0.23%)

AMZN

Amazon.com

$1,593.59

-26.41 (-1.63%)

CMCSA

Comcast

$38.60

0.11 (0.29%)

CMCSK

Comcast

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$16.46

-0.12 (-0.72%)

F

Ford

$9.05

-0.26 (-2.79%)

GM

General Motors

$35.76

0.21 (0.59%)

HMC

Honda

$28.21

0.01 (0.04%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$116.87

-0.02 (-0.02%)

VLKAY

Volkswagen

$0.00

(0.00%)

NYT

New York Times

$26.30

-0.2 (-0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 03

    Dec

  • 04

    Dec

  • 13

    Dec

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

NVS

Novartis

$87.74

0.52 (0.60%)

, DBVT

DBV Technologies

$16.70

0.31 (1.89%)

04:55
11/17/18
11/17
04:55
11/17/18
04:55
Conference/Events
American College of Allergy, Asthma & Immunology to hold a meeting »

2018 ACAAI Meeting will…

NVS

Novartis

$87.74

0.52 (0.60%)

DBVT

DBV Technologies

$16.70

0.31 (1.89%)

REGN

Regeneron

$345.10

3.56 (1.04%)

SHPG

Shire

$175.59

-3.39 (-1.89%)

TEVA

Teva

$22.25

-0.37 (-1.64%)

SNY

Sanofi

$45.11

0.56 (1.26%)

GSK

GlaxoSmithKline

$40.35

-0.06 (-0.15%)

AZN

AstraZeneca

$40.67

-0.685 (-1.66%)

CHD

Church & Dwight

$65.42

-0.39 (-0.59%)

BSX

Boston Scientific

$37.22

0.75 (2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 30

    Nov

  • 02

    Dec

  • 03

    Dec

  • 21

    Dec

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

  • 13

    May

MSI

Motorola Solutions

$129.97

0.72 (0.56%)

18:48
11/16/18
11/16
18:48
11/16/18
18:48
Hot Stocks
Motorola Solutions: ITC confirms Hytera products infringe Motorola patents »

Motorola Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 18

    Dec

  • 19

    Dec

PCG

PG&E

$24.39

6.62 (37.25%)

18:23
11/16/18
11/16
18:23
11/16/18
18:23
Periodicals
CPUC isn't ruling out board shuffle, breakup for PG&E, Bloomberg says »

The California Public…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABX

Barrick Gold

$13.04

0.05 (0.38%)

18:00
11/16/18
11/16
18:00
11/16/18
18:00
Periodicals
Barrick Gold looking to add more copper, bullion assets, Reuters reports »

Barrick Gold is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTR

Aqua America

$33.05

0.165 (0.50%)

17:57
11/16/18
11/16
17:57
11/16/18
17:57
Hot Stocks
Aqua America CEO acquires over 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRE

Real Estate SPDR

$33.45

0.445 (1.35%)

, XLB

S&P Select Materials SPDR

$55.23

0.53 (0.97%)

17:39
11/16/18
11/16
17:39
11/16/18
17:39
General news
Week ending ETF scorecard: Real Estate leads, Consumer Discretionary slumps »

S&P500 SECTORS: Real…

XLRE

Real Estate SPDR

$33.45

0.445 (1.35%)

XLB

S&P Select Materials SPDR

$55.23

0.53 (0.97%)

XLU

Utilities SPDR

$54.86

0.77 (1.42%)

XLI

Industrial Select Sector SPDR

$72.00

(0.00%)

XLV

Health Care Select Sector SPDR

$92.05

0.91 (1.00%)

XLF

Financial Select Sector

$26.78

0.03 (0.11%)

XLP

Consumer Staples Sector SPDR

$56.04

0.15 (0.27%)

XLE

Energy Select Sector SPDR

$67.23

0.76 (1.14%)

XLC

Communication Services Select Sector SPDR Fund

$44.88

-0.2 (-0.44%)

XLK

Technology Select Sector SPDR

$68.22

-0.1 (-0.15%)

XLY

Consumer Discretionary Sector SPDR

$106.37

-0.43 (-0.40%)

GLD

SPDR Gold Shares

$115.56

0.82 (0.71%)

SLV

iShares Silver Trust

$13.55

0.115 (0.86%)

USO

United States Oil Fund

$12.07

0.08 (0.67%)

UNG

United States Natural Gas Fund

$35.43

3.63 (11.42%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$83.24

-0.27 (-0.32%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$111.73

0.23 (0.21%)

TLT

iShares 20+ Year Treasury Bond Fund

$114.65

0.61 (0.53%)

IEF

iShares 7-10 Year Treasury Bond ETF

$101.13

0.3 (0.30%)

SHY

iShares 1-3 Year Treasury Bond

$83.13

0.08 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQST

Aquestive Therapeutics

$17.02

0.23 (1.37%)

17:36
11/16/18
11/16
17:36
11/16/18
17:36
Hot Stocks
Aquestive receives CRL from FDA for tadalafil oral film »

Aquestive Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

DAKT

Daktronics

$7.67

0.07 (0.92%)

17:35
11/16/18
11/16
17:35
11/16/18
17:35
Hot Stocks
Daktronics adopts new shareholder rights agreement »

Daktronics announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

TI

Telecom Italia

$6.02

0.12 (2.03%)

17:33
11/16/18
11/16
17:33
11/16/18
17:33
Periodicals
Gubitosi viewed as frontrunner for Telecom Italia CEO job, Reuters says »

Veteran Italian manager…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAXR

Maxar Technologies

$18.77

-0.59 (-3.05%)

17:30
11/16/18
11/16
17:30
11/16/18
17:30
Hot Stocks
Maxar Technologies shareholders approve U.S. domestication »

Maxar Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLUG

Plug Power

$1.83

(0.00%)

17:28
11/16/18
11/16
17:28
11/16/18
17:28
Syndicate
Breaking Syndicate news story on Plug Power »

Plug Power files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSB

GlobalSCAPE

$4.55

-0.02 (-0.44%)

17:22
11/16/18
11/16
17:22
11/16/18
17:22
Syndicate
Breaking Syndicate news story on GlobalSCAPE »

GlobalSCAPE files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQIX

Equinix

$388.18

2.67 (0.69%)

17:19
11/16/18
11/16
17:19
11/16/18
17:19
Hot Stocks
Equinix's Lee sells 2,792 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 10

    Dec

LMT

Lockheed Martin

$301.06

-4.42 (-1.45%)

17:17
11/16/18
11/16
17:17
11/16/18
17:17
Hot Stocks
Lockheed Martin awarded $282.09M Naval Sea Systems Command contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLGT

Teligent

$2.56

0.045 (1.79%)

17:16
11/16/18
11/16
17:16
11/16/18
17:16
Hot Stocks
Teligent receives notification of deficiency from Nasdaq »

Teligent said that on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STAF

Staffing 360 Solutions

$1.82

0.07 (4.00%)

17:16
11/16/18
11/16
17:16
11/16/18
17:16
Syndicate
Breaking Syndicate news story on Staffing 360 Solutions »

Staffing 360 Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

IMMR

Immersion

$9.56

-0.14 (-1.44%)

17:12
11/16/18
11/16
17:12
11/16/18
17:12
Hot Stocks
Breaking Hot Stocks news story on Immersion »

Man Group reports 4.84%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.